Treatment options for recurrent glioblastoma: Pitfalls and future trends

Expert Review of Anticancer Therapy

Volumn 9, Issue 5, 2009, Pages 613-619

  Franceschi, Enrico ^a   Tosoni, Alicia ^a   Bartolini, Stefania ^a   Mazzocchi, Valeria ^a   Fioravanti, Antonio ^a   Brandes, Alba A ^a  

^a BELLARIA HOSPITAL   (Italy)

Author keywords

Glioblastoma; Radiotherapy; Recurrent; Target therapy; Temozolomide

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CARMUSTINE; CEDIRANIB; CILENGITIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; IMATINIB; IRINOTECAN; LOMUSTINE; NITROSOUREA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TEMOZOLOMIDE;

BRACHYTHERAPY; BRAIN HEMORRHAGE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG RESPONSE; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; INTESTINE PERFORATION; MONOTHERAPY; PHOTODYNAMIC THERAPY; PROGRESSION FREE SURVIVAL; REOPERATION; REVIEW; STEREOTACTIC BODY RADIATION THERAPY; THROMBOSIS; UNSPECIFIED SIDE EFFECT; BRAIN TUMOR; MULTIMODALITY CANCER THERAPY; TUMOR RECURRENCE;

BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; GLIOBLASTOMA; HUMANS; NEOPLASM RECURRENCE, LOCAL;

EID: 68149165608     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/ERA.09.23     Document Type: Review

References (56)

1. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987-996 (2005).
2. Hoffman WF, Levin VA, Wilson CB. Evaluation of malignant glioma patients during the postirradiation period. J. Neurosurg. 50, 624-628 (1979).
3. Sheline GE, Wara WM, Smith V. Therapeutic irradiation and brain injury. Int. J. Radiat. Oncol. Biol. Phys. 6, 1215-1228 (1980).
4. Burger PC, Dubois PJ, Schold SC Jr et al. Computerized tomographic and pathologic studies of the untreated, quiescent, and recurrent glioblastoma multiforme. J. Neurosurg. 58, 159-169 (1983).
5. Dooms GC, Hecht S, Brant-Zawadzki M et al. Brain radiation lesions: MR imaging. Radiology 158, 149-155 (1986).
6. Tihan T, Barletta J, Parney I et al. Prognostic value of detecting recurrent glioblastoma multiforme in surgical specimens from patients after radiotherapy: should pathology evaluation alter treatment decisions? Hum. Pathol. 37, 272-282 (2006).
7. Rock JP, Scarpace L, Hearshen D et al. Associations among magnetic resonance spectroscopy, apparent diffusion coefficients, and image-guided histopathology with special attention to radiation necrosis. Neurosurgery 54, 1111-1117 (2004).
8. Tsuyuguchi N, Takami T, Sunada I et al. Methionine positron emission tomography for differentiation of recurrent brain tumor and radiation necrosis after stereotactic radiosurgery - in malignant glioma. Ann. Nucl. Med. 18, 291-296 (2004).
9. 18Ffluoroethyl)-L-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas. Neurosurgery 57, 505-511 (2005).
10. de Wit MC, de Bruin HG, Eijkenboom W et al. Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology 63, 535-537 (2004).
11. Chamberlain MC, Glantz MJ, Chalmers L et al. Early necrosis following concurrent temodar and radiotherapy in patients with glioblastoma. J. Neurooncol. 82(1), 81-83 (2006).
12. Taal W, Brandsma D, de Bruin HG et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 113, 405-410 (2008).
13. Brandes AA, Franceschi E, Tosoni A et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J. Clin. Oncol. 26, 2192-2197 (2008).
14. Brandes AA, Tosoni A, Spagnolli F et al. Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology. Neuro. Oncol. 10(3), 361-367 (2008).
15. Brandsma D, Stalpers L, Taal W et al. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol. 9, 453-461 (2008).
16. Brem H, Piantadosi S, Burger PC et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 345, 1008-1012 (1995).
17. Young B, Oldfield EH, Markesbery WR et al. Reoperation for glioblastoma. J. Neurosurg. 55, 917-921 (1981).
18. Barker FG 2nd, Chang SM, Gutin PH et al. Survival and functional status after resection of recurrent glioblastoma multiforme. Neurosurgery 42, 709-720 (1998).
19. Nieder C, Adam M, Molls M, Grosu AL. Therapeutic options for recurrent high-grade glioma in adult patients: recent advances. Crit. Rev. Oncol. Hematol. 60, 181-193 (2006).
20. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for Phase II studies of supratentorial malignant glioma. J. Clin. Oncol. 8, 1277-1280 (1990).
21. Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto Phase II clinical trials. J. Clin. Oncol. 17, 2572-2578 (1999).
22. Ballman KV, Buckner JC, Brown PD et al. The relationship between six-month progression-free survival and 12-month overall survival end points for Phase II trials in patients with glioblastoma multiforme. Neuro. Oncol. 9, 29-38 (2007).
23. Osoba D, Aaronson NK, Muller M et al. Effect of neurological dysfunction on health-related quality of life in patients with high-grade glioma. J. Neurooncol. 34, 263-278 (1997).
24. Brandes AA, Fiorentino MV. The role of chemotherapy in recurrent malignant gliomas: an overview. Cancer Invest. 14, 551-559 (1996).
25. Moscatello DK, Ramirez G, Wong AJ. A naturally occurring mutant human epidermal growth factor receptor as a target for peptide vaccine immunotherapy of tumors. Cancer Res. 57, 1419-1424 (1997).
26. Brandes AA, Tosoni A, Basso U et al. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a Phase II study of the Gruppo Italiano Cooperative di Neuro-Oncologia (GICNO). J. Clin. Oncol. 22, 4779-4786 (2004).
27. Groves MD, Puduvalli VK, Hess KR et al. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J. Clin. Oncol. 20, 1383-1388 (2002).
28. Brandes AA, Basso U, Reni M et al. First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a Phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia. J. Clin. Oncol. 22, 1598-1604 (2004).
29. Jaeckle KA, Hess KR, Yung WK et al. Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study. J. Clin. Oncol. 21, 2305-2311 (2003).
30. Cokgor I, Friedman HS, Friedman AH. Chemotherapy for adults with malignant glioma. Cancer Invest. 17, 264-272 (1999).
31. Franceschi E, Omuro AM, Lassman AB et al. Salvage temozolomide for prior temozolomide responders. Cancer 104, 2473-2476 (2005).
32. Perry J, Mason W, Belanger K et al. The Temozolomide RESCUE study: a Phase II trial of continuous (28/28) dose-intense temozolomide (TMZ) after progression on conventional 5/28 day TMZ in patients with recurrent malignant glioma. Clin. Oncol. 26(Suppl. 15) (2008) (Abstract 2010).
33. Brandes AA, Tosoni A, Franceschi E et al. Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a Phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Cancer Chemother. Pharmacol. (Epub ahead of print) (2009).
34. Fabrini MG, Silvano G, Lolli I et al. A multi-institutional Phase II study on second-line Fotemustine chemotherapy in recurrent glioblastoma. J. Neurooncol. 92(1), 79-86 (2008).
35. Scoccianti S, Detti B, Sardaro A et al. Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience. Anticancer Drugs 19, 613-620 (2008).
36. Rich JN, Reardon DA, Peery T et al. Phase II trial of gefitinib in recurrent glioblastoma. J. Clin. Oncol. 22, 133-142 (2004).
37. Franceschi E, Cavallo G, Lonardi S et al. Gefitinib in patients with progressive high-grade gliomas: a multicentre Phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Br. J. Cancer 96(7), 1047-1051 (2007).
38. Haas-Kogan DA, Prados MD, Tihan T et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J. Natl Cancer Inst. 97, 880-887 (2005).
39. Mellinghoff IK, Wang MY, Vivanco I et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med. 353, 2012-2024 (2005).
40. van den Bent MJ, Brandes AA, Rampling R et al. Randomized Phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J. Clin. Oncol. 27, 1268-1274 (2009).
41. de Groot JF, Gilbert MR, Aldape K et al. Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma. J. Neurooncol. 90, 89-97 (2008).
42. Vredenburgh JJ, Desjardins A, Herndon JE 2nd et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin. Cancer Res. 13, 1253-1259 (2007).
43. Vredenburgh JJ, Desjardins A, Herndon JE 2nd et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J. Clin. Oncol. 25, 4722-4729 (2007).
44. Bokstein F, Shpigel S, Blumenthal DT. Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors. Cancer 112, 2267-2273 (2008).
45. Cloughesy TF, Prados MD, Wen PY et al. A Phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM). J. Clin. Oncol. 26 (Suppl.) (2008) (Abstract 2010b).
46. Kreisl TN, Kim L, Moore K et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J. Clin. Oncol. 27(5), 740-745 (2008).
47. Levin VA, Crafts DC, Norman DM et al. Criteria for evaluating patients undergoing chemotherapy for malignant brain tumors. J. Neurosurg. 47, 329-335 (1977).
48. Norden AD, Drappatz J, Muzikansky A et al. An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma. J. Neurooncol. 92, 149-155 (2009).
49. 18Ffluorothymidine positron emission tomography: a pilot study. J. Clin. Oncol. 25, 4714-4721 (2007).
50. Batchelor TT, Sorensen AG, di Tomaso E et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11, 83-95 (2007).
51. Norden AD, Drappatz J, Ciampa AS et al. Colon perforation during antiangiogenic therapy for malignant glioma. Neuro. Oncol. 11, 92-95 (2009).
52. Stupp R, Goldbrunner R, Neyns B et al. Phase I/IIa trial of cilengitide (EMD121974) and temozolomide with concomitant radiotherapy, followed by temozolomide and cilengitide maintenance therapy in patients (pts) with newly diagnosed glioblastoma (GBM). J. Clin. Oncol. 25(Supp.18) (2007) (Abstract 2000).
53. Reardon DA, Fink KL, Mikkelsen T et al. Randomized Phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J. Clin. Oncol. 26, 5610-5617 (2008).
54. Raymond E, Brandes AA, Dittrich C et al. Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. J. Clin. Oncol. 26, 4659-4665 (2008).
55. Jefferies S, Burton K, Jones P, Burnet N. Interpretation of early imaging after concurrent radiotherapy and temozolomide for glioblastoma. Clin. Oncol. (R. Coll. Radial.) 19(Supp.), 33 (2007).
56. Galanis E, Buckner JC, Maurer MJ et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J. Clin. Oncol. 23, 5294-5304 (2005).